News / Taiwan / economic_daily
BRM424 Phase II Data Prompts Allgenesis to Target Year-End Licensing Deal
Health Technology · Biotechnology · economic_daily · 2026-09-22
6885
Allgenesis reports positive Phase II results for its corneal nerve-healing drug BRM424, with management aiming to secure international licensing by year-end.
What Happened
Clinical Performance: Allgenesis announced positive Phase II clinical trial results for its neurotrophic keratitis (NK) drug candidate, BRM424. The study showed that 50% of the 14 participants achieved complete corneal healing within 28 days of treatment.
Licensing Strategy: Chairman Lin Chun stated that the company is actively pursuing international licensing agreements for BRM424. The management team has set a target to finalize these strategic partnerships before the end of the current year.
Market Challenges: Current standard-of-care treatments like Oxervate face significant hurdles, including high costs, strict cold-chain requirements, and severe side effects like eye pain. BRM424 aims to address these limitations, potentially offering a more patient-friendly and accessible alternative.
Growth Potential: The company believes the actual market demand for NK treatments exceeds initial estimates. Furthermore, the drug's potential to stimulate ocular nerve regeneration represents a significant breakthrough in the field of ophthalmology.